Literature DB >> 1686145

Coagulation disorders in experimentally induced acute mouse malaria.

G Reiner1, R Clemens, H L Bock, B Enders.   

Abstract

The development of coagulation disorders was studied in murine malaria. Plasmodium vinckei was chosen following an initial experiment because onset and duration of parasitemia were more suitable for hemostasiological studies than in the short-lasting infection, caused by P. berghei. Evaluation of the time courses of hematocrit, platelets, antithrombin (AT) III activity, Factor V activity and parasitemia showed a significant decrease in platelets, hematocrit, Factor V and AT III activity during the course of infection. The obtained data strongly suggest the development of a disseminated intravascular coagulation in mice during the terminal phase of murine malaria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686145     DOI: 10.1016/0001-706x(91)90073-s

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

1.  A chronic scheme of cranial window preparation to study pial vascular reactivity in murine cerebral malaria.

Authors:  Peng Kai Ong; Diana Meays; John A Frangos; Leonardo J M Carvalho
Journal:  Microcirculation       Date:  2013-07       Impact factor: 2.628

2.  Malaria-induced murine pregnancy failure: distinct roles for IFN-gamma and TNF.

Authors:  Jayakumar S Poovassery; Demba Sarr; Geoffrey Smith; Tamas Nagy; Julie M Moore
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

3.  Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria.

Authors:  Ivo M B Francischetti; Emile Gordon; Bruna Bizzarro; Nidhi Gera; Bruno B Andrade; Fabiano Oliveira; Dongying Ma; Teresa C F Assumpção; José M C Ribeiro; Mirna Pena; Chen-Feng Qi; Ababacar Diouf; Samuel E Moretz; Carole A Long; Hans C Ackerman; Susan K Pierce; Anderson Sá-Nunes; Michael Waisberg
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.